Application of OMICS technologies in occupational and environmental health research; current status and projections

Occupational and Environmental Medicine

Volumn 67, Issue 2, 2010, Pages 136-143

  Vlaanderen, Jelle ^a   Moore, L E ^b   Smith, M T ^c   Lan, Q ^b   Zhang, L ^c   Skibola, C F ^c   Rothman, N ^b   Vermeulen, R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; BENZENE; BIOLOGICAL MARKER;

ENVIRONMENTAL HEALTH; GENE EXPRESSION PROFILING; GENOTYPE; MEDICAL RESEARCH; METABOLOMICS; MICROARRAY ANALYSIS; OBSERVATIONAL STUDY; OCCUPATIONAL HEALTH; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; VALIDATION STUDY;

ARSENIC; BENZENE; BIOLOGICAL MARKERS; ENVIRONMENTAL MEDICINE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; OCCUPATIONAL DISEASES; OCCUPATIONAL MEDICINE; PROTEOMICS;

EID: 76249115614     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oem.2008.042788     Document Type: Review

References (98)

1. Smith MT, Vermeulen R, Li G, et al. Use of 'Omic' technologies to study humans exposed to benzene. Chem Biol Interact 2005;153-154:123-7.
2. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33.
3. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51.
4. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:1847-50.
5. Smith MT. Future perspectives of molecular cancer epidemiology. EJC Supplements 2008;6:188.
6. Syvänen A-C. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nature Reviews Genetics 2001;2:930-42.
7. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
8. Eichler EE, Nickerson DA, Altshuler D, et al. Completing the map of human genetic variation. Nature 2007;447:161-5.
9. Rocha D, Gut I, Jeffreys AJ, et al. Seventh international meeting on single nucleotide polymorphism and complex genome analysis: 'ever bigger scans and an increasingly variable genome'. Hum Genet 2006;119:451-6.
10. Engle LJ, Simpson CL, Landers JE. Using high-throughput SNP technologies to study cancer. Oncogene 2006;25:1594-601.
11. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001;294:1719-23.
12. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008;40:695-701.
13. Castro-Giner F, Kauffmann F, de Cid R, et al. Gene-environment interactions in asthma. Occup Environ Med 2006;63:776-86, 761.
14. Colilla S, Kantoff PW, Neuhausen SL, et al. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2006;27:599-605.
15. Mukherjee B, Chatterjee N. Exploiting gene-environment independence for analysis of case-control studies: an empirical Bayes-type shrinkage estimator to trade-off between bias and efficiency. Biometrics 2008;64:685-94.
16. Murcray CE, Lewinger JP, Gauderman WJ. Gene-environment interaction in genome-wide association studies. Am J Epidemiol 2009;169:219-26.
17. Wakefield J, De Vocht F, Hung RJ. Bayesian mixture modeling of gene-environment and gene-gene interactions. Genet Epidemiol In press.
18. Shlien A, Malkin D. Copy number variations and cancer. Genome Med 2009;1:62.
19. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
20. Costa JL, Meijer G, Ylstra B, et al. Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin Radiat Oncol 2008;18:98-104.
21. Benhamou S, Lee WJ, Alexandrie AK, et al. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002;23:1343-50.
22. Carlsten C, Sagoo GS, Frodsham AJ, et al. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and metaanalysis. Am J Epidemiol 2008;167:759-74.
23. Crosbie PA, Barber PV, Harrison KL, et al. GSTM1 copy number and lung cancer risk. Mutat Res 2009;664:1-5.
24. Sorensen M, Raaschou-Nielsen O, Brasch-Andersen C, et al. Interactions between GSTM1, GSTT1 and GSTP1 polymorphisms and smoking and intake of fruit and vegetables in relation to lung cancer. Lung Cancer 2007;55:137-44.
25. Manning AT, Garvin JT, Shahbazi RI, et al. Molecular profiling techniques and bioinformatics in cancer research. Eur J Surg Oncol 2007;33:255-65.
26. Nachtomy O, Shavit A, Yakhini Z. Gene expression and the concept of the phenotype. Stud Hist Philos Biol Biomed Sci 2007;38:238-54.
27. Celis JE, Kruhoffer M, Gromova I, et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 2000;480:2-16.
28. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet 2006;15:R95-101.
29. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-40.
30. Bird A. Perceptions of epigenetics. Nature 2007;447:396-8.
31. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457- 63.
32. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9:465-76.
33. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16:383-93.
34. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-98.
35. Higgs DR, Vernimmen D, Hughes J, et al. Using genomics to study how chromatin influences gene expression. Ann Rev Genomics Hum Genet 2007;8:299-325.
36. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007;8:253-62.
37. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
38. Liu L, Wylie RC, Andrews LG, et al. Aging, cancer and nutrition: the DNA methylation connection. Mech Ageing Dev 2003;124:989-98.
39. Moore LE, Huang WY, Chung J, et al. Epidemiologic considerations to assess altered DNA methylation from environmental exposures in cancer. Ann N Y Acad Sci 2003;983:181-96.
40. Costa FF. Non-coding RNAs: lost in translation? Gene 2007;386:1-10.
41. de Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53.
42. Moss TJ, Wallrath LL. Connections between epigenetic gene silencing and human disease. Mutat Res 2007;618:163-74.
43. Sellers TA, Yates JR. Review of proteomics with applications to genetic epidemiology. Genet Epidemiol 2003;24:83-98.
44. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007;18:1057-71.
45. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452:571-9.
46. Wingren C, Borrebaeck CA. Antibody microarrays: current status and key technological advances. Omics 2006;10:411-27.
47. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008;453:396-400.
48. Claudino WM, Quattrone A, Biganzoli L, et al. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-6.
49. Garcia-Closas M, Vermeulen R, Sherman M, et al. Application of biomarkers in cancer epidemiology. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 2006:70-88.
50. Vineis P, Gallo V. The epidemiological theory: principles of biomarker validation. In: Vineis P, Gallo V, eds. Epidemiological concepts of validation of biomarkers for the identification/quantification of environmental carcinogenic exposures. Lodz: Nofer Institute of Occupational Medicine, 2007.
51. Duncan MW. Omics and its 15 minutes. Exp Biol Med (Maywood) 2007;232:471-2.
52. Morrison N, Wood AJ, Hancock D, et al. Annotation of environmental OMICS data: application to the transcriptomics domain. Omics 2006;10:172-8.
53. Wilkes T, Laux H, Foy CA. Microarray data quality - review of current developments. Omics 2007;11:1-13.
54. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
55. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995;310:170.
56. Semmes OJ. The "omics" haystack: defining sources of sample bias in expression profiling. Clin Chem 2005;51:1571-2.
57. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
58. Dumeaux V, Borresen-Dale AL, Frantzen JO, et al. Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study. Breast Cancer Res 2008;10:R13.
59. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: B: Are the results of the study valid? JAMA 2009;301:191-7.
60. Yesupriya A, Evangelou E, Kavvoura FK, et al. Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment. BMC Med Res Methodol 2008;8:31.
61. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Eur J Epidemiol 2009;24:37-55.
62. Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis. Genome Res 2007;17:1537-45.
63. Khatri P, Draghici S. Ontological analysis of gene expression data: current tools, limitations, and open problems. Bioinformatics 2005;21:3587-95.
64. Weniger M, Engelmann JC, Schultz J. Genome expression pathway analysis tool-analysis and visualization of microarray gene expression data under genomic, proteomic and metabolic context. BMC Bioinformatics 2007;8:179.
65. Nock NL, Larkin EK, Morris NJ, et al. Modeling the complex gene x environment interplay in the simulated rheumatoid arthritis GAW15 data using latent variable structural equation modeling. BMC Proc 2007;1(Suppl 1):S118.
66. The Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res 2001;11:1425-33.
67. Lemberger T. Systems biology in human health and disease. Mol Syst Biol 2007;3:136.
68. Studer SM, Kaminski N. Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc 2007;4:85-91.
69. Lund E, Dumeaux V. Systems epidemiology in cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2954-7.
70. Lan Q, Zhang L, Shen M, et al. Polymorphisms in cytokine and cellular adhesion molecule genes and susceptibility to hematotoxicity among workers exposed to benzene. Cancer Res 2005;65:9574-81.
71. Shen M, Lan Q, Zhang L, et al. Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity. Carcinogenesis 2006;27:2083-9.
72. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science 2004;306:1774-6.
73. Lan Q, Zhang L, Shen M, et al. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity. Carcinogenesis 2009;30:50-8.
74. Argos M, Kibriya MG, Parvez F, et al. Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. Cancer Epidemiol Biomarkers Prev 2006;15:1367-75.
75. Gillis B, Gavin IM, Arbieva Z, et al. Identification of human cell responses to benzene and benzene metabolites. Genomics 2007;90:324-33.
76. Smith MT. Misuse of genomics in assigning causation in relation to benzene exposure. Int J Occup Environ Health 2008;14:144-6.
77. Chen Y, Li G, Yin S, et al. Genetic polymorphisms involved in toxicant-metabolizing enzymes and the risk of chronic benzene poisoning in Chinese occupationally exposed populations. Xenobiotica 2007;37:103-12.
78. Gu SY, Zhang ZB, Wan JX, et al. Genetic polymorphisms in CYP1A1, CYP2D6, UGT1A6, UGT1A7, and SULT1A1 genes and correlation with benzene exposure in a Chinese occupational population. J Toxicol Environ Health A 2007;70:916-24.
79. Kim YJ, Choi JY, Paek D, et al. Association of the NQO1, MPO, and XRCC1 polymorphisms and chromosome damage among workers at a petroleum refinery. J Toxicol Environ Health A 2008;71:333-41.
80. Zhang Z, Wan J, Jin X, et al. Genetic polymorphisms in XRCC1, APE1, ADPRT, XRCC2, and XRCC3 and risk of chronic benzene poisoning in a Chinese occupational population. Cancer Epidemiol Biomarkers Prev 2005;14:2614-9.
81. McCarty KM, Chen YC, Quamruzzaman Q, et al. Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ Health Perspect 2007;115:341-5.
82. Breton CV, Zhou W, Kile ML, et al. Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis 2007;28:1520-5.
83. Schlawicke Engstrom K, Broberg K, Concha G, et al. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 2007;115:599-605.
84. Steinmaus C, Moore LE, Shipp M, et al. Genetic polymorphisms in MTHFR 677 and 1298, GSTM1 and T1, and metabolism of arsenic. J Toxicol Environ Health A 2007;70:159-70.
85. Applebaum KM, Karagas MR, Hunter DJ, et al. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect 2007;115:1231-6.
86. Hsu LI, Chiu AW, Pu YS, et al. Comparative genomic hybridization study of arsenicexposed and non-arsenic-exposed urinary transitional cell carcinoma. Toxicol Appl Pharmacol 2008;227:229- 38.
87. Moore LE, Smith AH, Eng C, et al. Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 2002;94:1688-96.
88. Bollati V, Baccarelli A, Hou L, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 2007;67:876-80.
89. Marsit CJ, Karagas MR, Schned A, et al. Carcinogen exposure and epigenetic silencing in bladder cancer. Ann N Y Acad Sci 2006;1076:810-21.
90. Chanda S, Dasgupta UB, Guhamazumder D, et al. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci 2006;89:431-7.
91. Pilsner JR, Liu X, Ahsan H, et al. Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults. Am J Clin Nutr 2007;86:1179-86.
92. Forrest MS, Lan Q, Hubbard AE, et al. Discovery of novel biomarkers by microarray analysis of peripheral blood mononuclear cell gene expression in benzene-exposed workers. Environ Health Perspect 2005;113:801-7.
93. Fry RC, Navasumrit P, Valiathan C, et al. Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet 2007;3:e207.
94. Wu MM, Chiou HY, Ho IC, et al. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect 2003;111:1429-38.
95. Joo WA, Sul D, Lee DY, et al. Proteomic analysis of plasma proteins of workers exposed to benzene. Mutat Res 2004;558:35-44.
96. Vermeulen R, Lan Q, Zhang L, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci U S A 2005;102:17041-6.
97. Zhai R, Su S, Lu X, et al. Proteomic profiling in the sera of workers occupationally exposed to arsenic and lead: identification of potential biomarkers. Biometals 2005;18:603-13.
98. Hegedus CM, Skibola CF, Warner M, et al. Decreased urinary beta-defensin-1 expression as a biomarker of response to arsenic. Toxicol Sci 2008;106:74-82.